Personalized corticosteroid treatment for pneumonia
Individualizing Corticosteroid Use in Pneumonia
This study is testing if giving personalized doses of corticosteroids based on a blood marker can help hospitalized adults with pneumonia feel better while reducing side effects.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 24 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Mayo Clinic Academic / other |
| Locations | 1 site (Rochester, Minnesota) |
| Trial ID | NCT05334316 on ClinicalTrials.gov |
What this trial studies
This study aims to personalize corticosteroid treatment for hospitalized adults with community-acquired pneumonia by comparing standard care to an individualized dosing strategy based on the inflammatory marker C-reactive protein (CRP). Researchers will assess the appropriate steroid dosage to minimize exposure and potential side effects while maximizing the therapeutic benefits. The goal is to enhance patient outcomes through tailored treatment approaches.
Who should consider this trial
Good fit: Ideal candidates are hospitalized adults aged 18 and older diagnosed with community-acquired pneumonia.
Not a fit: Patients with contraindications to corticosteroids, such as adrenal insufficiency or those receiving comfort care, may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more effective and safer corticosteroid use in pneumonia patients.
How similar studies have performed: Other studies have explored individualized treatment approaches, but this specific strategy focusing on CRP in pneumonia is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Hospitalized adult (≥ 18 years) patients. * Community acquired pneumonia. Exclusion Criteria: * Contraindications or unwillingness to use corticosteroids by patient or provider. * History of adrenal insufficiency, septic shock, or another absolute indication for steroid use. * Suspected pulmonary vasculitis or other autoimmune pulmonary disorder. * Positive pregnancy test * Comfort care.
Where this trial is running
Rochester, Minnesota
- Mayo Clinic Rochester — Rochester, Minnesota, United States (Recruiting)
Study contacts
- Principal investigator: Yewande Odeyemi, MBBS — Mayo Clinic
- Study coordinator: Yewande Odeyemi, M.B.B.S.
- Email: odeyemi.yewande@mayo.edu
- Phone: 507-284-2494
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.